Rallidis LS, Tsamoulis D, Papathanasiou KA, Kalogeras P, et al. Eligibility for icosapent ethyl 1-3 months after acute coronary syndrome and the risk for myocardial re-infarction: Data from the CALLINICUS-Hellas Registry. Int J Cardiol 2025;440:133684.
PMID: 40752806